This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Edwards, K. L. Articles by Ceja, M. E. Search for Related Content Social Bookmarking                         What's this?

Gatifloxacin-Induced Hyperglycemia: A Review of 4 Cases and the Literature

Texas Tech University Health Sciences Center, School of Pharmacy — Dallas/Fort Worth Regional Center, Department of Pharmacy Practice, Dallas, Krystal.Edwards{at}ttuhsc.edu

Ronald G. Hall, PharmD, BCPS

Texas Tech University Health Sciences Center, School of Pharmacy — Dallas/Fort Worth Regional Center, Department of Pharmacy Practice, Dallas

Maria Estela Ceja, PharmD

Texas Tech University Health Sciences Center, School of Pharmacy — Dallas/Fort Worth Regional Center, Department of Pharmacy Practice, Dallas

Gatifloxacin, a broad-spectrum fluoroquinolone, has recently been voluntarily withdrawn by Bristol-Myers Squibb from the market secondary to dysglycemic events associated with this agent. Risk factors for this adverse event include diabetes and those who are elderly (65 years of age or older), have renal insufficiency, or take glucose altering medications. The mechanism for this adverse reaction is not fully understood. However, it is theorized that there is an association between accumulation of gatifloxacin (particularly in elderly patients or those with renal insufficiency) and dysglycemic events with gatifloxacin. A review of the literature found 13 reported cases of hyperglycemia induced by gatifloxacin and 2 clinical trials evaluating gatifloxacin's association with hyperglycemia. Similarly to other reported cases, the authors' 4 outpatients were initiated on gatifloxacin therapy and subsequently had developed hyperglycemia during gatifloxacin therapy. Prior to the multiple observations of dysglycemias associated with gatifloxacin, this medication was widely used and thought to have an excellent safety profile. Hence, clinicians should be vigilant and exercise caution with newly approved medications.

Key Words: gatifloxacin • Tequin® • hyperglycemia • dysglycemia • glucose.

Journal of Pharmacy Practice, Vol. 20, No. 1, 93-102 (2007)
DOI: 10.1177/0897190007303053


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?